EEF2K and triple-negative breast carcinoma: In another study, in vivo administration of thymoquinone (20 and 100 mg/kg) significantly decreased the progression of MDA-MB-231 tumors and inhibited the eukaryotic elongation factor 2 kinase (eEF-2K) in an orthotopic tumor mouse model of triple-negative breast cancer [250].